Brian Springthorpe
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Brian Springthorpe.
Nature Reviews Drug Discovery | 2007
Paul D. Leeson; Brian Springthorpe
The application of guidelines linked to the concept of drug-likeness, such as the rule of five, has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity — the most important drug-like physical property — include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Archive | 1999
Simon Guile; David Hardern; Brian Springthorpe; Paul Willis
Archive | 2000
Stephen Thom; Andrew Baxter; Nicholas Kindor; Thomas Mcinally; Brian Springthorpe; Matthew Perry; David Harden; Richard Evans; David Marriott
Archive | 1999
David Hardem; Anthony Ingall; Brian Springthorpe; Paul Willis; Simon Guile
Archive | 2003
Richard Evans; Matthew AstraZeneca R D Charnwood Perry; Brian Springthorpe
Archive | 1997
Roger Victor Bonnert; Anthony Ingall; Brian Springthorpe; Paul Willis
Archive | 1998
Simon Guile; Anthony Ingall; Brian Springthorpe; Paul Willis
Archive | 2003
Christopher Luckhurst; Matthew Perry; Brian Springthorpe
Archive | 2000
Simon D. Guile; Brian Springthorpe
Archive | 2007
Peter Cage; Mark Furber; Christopher Luckhurst; Matthew Perry; Brian Springthorpe